Mark T Orr - JoVE Visualize

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Filters

Mark T Orr

Showing results (41-50 of 50) with videos related to

Pageof 5

Sort By:

You have reached the last page of results.This site can display upto 50 results.

NPJ Vaccines|January 10, 2019

Reprogramming the adjuvant properties of aluminum oxyhydroxide with nanoparticle technologyMark T Orr, Amit P Khandhar, Emilie Seydoux, et al.

NPJ Vaccines|June 15, 2018

Adjuvant composition and delivery route shape immune response quality and protective efficacy of a recombinant vaccine for Entamoeba histolyticaMayuresh M Abhyankar, Mark T Orr, Susan Lin, et al.

Heliyon|June 27, 2023

Stressed stability and protective efficacy of lead lyophilized formulations of ID93+GLA-SE tuberculosis vaccineMichelle C Archer, Joseph McCollum, Christopher Press, et al.

International Journal of Nanomedicine|July 10, 2018

Development of a thermostable nanoemulsion adjuvanted vaccine against tuberculosis using a design-of-experiments approachRyan M Kramer, Michelle C Archer, Mark T Orr, et al.

Clinical & Translational Immunology|December 20, 2016

A structure-function approach to optimizing TLR4 ligands for human vaccinesDarrick Carter, Christopher B Fox, Tracey A Day, et al.

Journal of Controlled Release : Official Journal of the Controlled Release Society|November 17, 2016

Adsorption of a synthetic TLR7/8 ligand to aluminum oxyhydroxide for enhanced vaccine adjuvant activity: A formulation approachChristopher B Fox, Mark T Orr, Neal Van Hoeven, et al.

NPJ Vaccines|February 16, 2023

Semi-synthetic terpenoids with differential adjuvant properties as sustainable replacements for shark squalene in vaccine emulsionsKarl J Fisher, Robert Kinsey, Raodoh Mohamath, et al.

Clinical & Translational Immunology|July 16, 2015

From mouse to man: safety, immunogenicity and efficacy of a candidate leishmaniasis vaccine LEISH-F3+GLA-SERhea N Coler, Malcolm S Duthie, Kimberly A Hofmeyer, et al.

Frontiers in Immunology|July 12, 2021

Optimizing a Multi-Component Intranasal Entamoeba Histolytica Vaccine Formulation Using a Design of Experiments StrategyMayuresh M Abhyankar, Mark T Orr, Robert Kinsey, et al.

Cancers|March 13, 2024

Preclinical Characterization of the Anti-Leukemia Activity of the CD33/CD16a/NKG2D Immune-Modulating TriNKET® CC-96191Margaret C Lunn-Halbert, George S Laszlo, Sarah Erraiss, et al.

Pageof 5

Search research articles

Showing results (41-50 of 50) with videos related to

Sort By:

Pageof 5

You have reached the last page of results.This site can display upto 50 results.

NPJ Vaccines|January 10, 2019

Reprogramming the adjuvant properties of aluminum oxyhydroxide with nanoparticle technologyMark T Orr, Amit P Khandhar, Emilie Seydoux, et al.

NPJ Vaccines|June 15, 2018

Heliyon|June 27, 2023

Stressed stability and protective efficacy of lead lyophilized formulations of ID93+GLA-SE tuberculosis vaccineMichelle C Archer, Joseph McCollum, Christopher Press, et al.

International Journal of Nanomedicine|July 10, 2018

Development of a thermostable nanoemulsion adjuvanted vaccine against tuberculosis using a design-of-experiments approachRyan M Kramer, Michelle C Archer, Mark T Orr, et al.

Clinical & Translational Immunology|December 20, 2016

A structure-function approach to optimizing TLR4 ligands for human vaccinesDarrick Carter, Christopher B Fox, Tracey A Day, et al.

Journal of Controlled Release : Official Journal of the Controlled Release Society|November 17, 2016

Adsorption of a synthetic TLR7/8 ligand to aluminum oxyhydroxide for enhanced vaccine adjuvant activity: A formulation approachChristopher B Fox, Mark T Orr, Neal Van Hoeven, et al.

NPJ Vaccines|February 16, 2023

Semi-synthetic terpenoids with differential adjuvant properties as sustainable replacements for shark squalene in vaccine emulsionsKarl J Fisher, Robert Kinsey, Raodoh Mohamath, et al.

Clinical & Translational Immunology|July 16, 2015

From mouse to man: safety, immunogenicity and efficacy of a candidate leishmaniasis vaccine LEISH-F3+GLA-SERhea N Coler, Malcolm S Duthie, Kimberly A Hofmeyer, et al.

Frontiers in Immunology|July 12, 2021

Optimizing a Multi-Component Intranasal Entamoeba Histolytica Vaccine Formulation Using a Design of Experiments StrategyMayuresh M Abhyankar, Mark T Orr, Robert Kinsey, et al.

Cancers|March 13, 2024

Preclinical Characterization of the Anti-Leukemia Activity of the CD33/CD16a/NKG2D Immune-Modulating TriNKET® CC-96191Margaret C Lunn-Halbert, George S Laszlo, Sarah Erraiss, et al.

Pageof 5